Five months after launching, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round to support the clinical development of a cancer asset licensed from Eli Lilly and advance the company’s precision proteomics platform.

Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.

Seagen (formerly known as Seattle Genetics) forged an exclusive licensing agreement with China’s RemeGen to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC).

Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond the company’s newly approved aducanumab hit a clinical snag as the anti-tau antibody gosuranemab failed to meet endpoints in a Phase II study and was discontinued.

Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China

ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.

Business updates for various pharma and life science companies around the globe.

Machine learning and artificial intelligence (AI) may resoundingly improve on traditional methods of drug development by biopharmaceutical companies.

The U.S. Food and Drug Administration rejected Sunovion Pharmaceuticals’ experimental treatment apomorphine sublingual film (APL-130277) for OFF episodes of Parkinson’s disease.

Privately held Tizona Therapeutics snagged $105 million in upfront cash as the company’s cancer antibody TTX-030 is the centerpiece of a collaborative effort with Illinois-based AbbVie.